tbuckley/cabot-search huggingface dataset:
Un service de médecins de garde comme site de surveillance sentinelle de la grippe
Authors: J Turner, H Kelly
Journal: Eurosurveillance (2005)

La surveillance de la grippe dans les pays de l’Union europeenne comprend un reseau sentinelle de medecins generalistes qui declarent les cas de syndromes grippaux (SG), le recueil des echantillons pour les analyses virologiques et les declarations des laboratoires des diagnostics de grippe. A Victoria, en Australie, il existe un systeme similaire de surveillance sentinelle. Les SG y sont definis par une fievre, une toux et de la fatigue, et les saisons de grippe correspondent a des seuils. Cependant, la coordination des generalistes sentinelle peut etre couteuse tant en termes de temps qu’en termes de moyens. Pendant les deux dernieres saisons grippales, un service de medecins de garde a ete utilise comme site sentinelle pour la surveillance de la grippe. A notre connaissance, il n’existe pas de systeme equivalent ailleurs dans le monde. Les comparaisons aussi bien retrospectives que prospectives ont montre que les profils de surveillance des SG des cabinets de medecine generale sentinelle sont tres proches de ceux du service de medecins de garde. Grâce a sa rapidite et sa flexibilite, a sa variete de patients et son etendue geographique, la surveillance par un service de medecins de garde peut remplacer la surveillance sentinelle. Elle peut egalement jouer un role dans la detection de profils de maladies emergentes. Il est fort probable que ce systeme valable en Australie puisse egalement l’etre dans les pays de l’Union Europeenne.
Prognostic implication of inflammation-based prognostic scores in patients with intrahepatic cholangiocarcinoma (iCCA) treated with first-line Gemcitabine plus Cisplatin (GEMCIS)
Authors: H. Cho, C. Yoo, K-P. Kim, H-M. Chang, B-Y. Ryoo
Journal: Annals of Oncology (2017)
Somatic versus germline BRCA mutations screening in ovarian cancer.
Authors: Hugo SM Nunes, Patricia Machado, Sofia Fragoso, Sidonia Santos, Fernanda Silva, Ana Felix, Ana Luís, Ana Opiniao, Ana Clara, Sandra Bento, Ana Miranda, Ana Francisca, Fatima H. Vaz
Journal: Journal of Clinical Oncology (2017)

e13100 Background: ovarian cancer (OC) with germinal or somatic BRCA mutations responds better to platinum and to PARP-inhibitors. There is great enthusiasm about BRCA somatic screening. Our aim was to analyse the correlation between BRCA somatic and germline mutational profile. Methods: a cohort of 23 pts was obtained by cross-linking OC pts from the South Portuguese Cancer Registry, between 2009-2014 and BRCA mutation carriers identified in our Clinic. Medical records were reviewed: demographic and clinico-pathologic data obtained. Germinal screening: pts were pre-screened for the BRCA2 Portuguese founder mutation (PFM), analysed for BRCA point mutations (different screening methodologies were used in diagnostic timeline: initially CSGE, then CSCE and finally NGS) and for large rearrangements by MLPA. Somatic screening: DNA was extracted from 5 sections of 10µm of FFPE tissue and analysed for BRCA1/2 genes by NGS. Results: clinico-pathological features of the 23 pts revealed mainly high-grade serous histology (96%). Mean age at diagnosis was 54 years old (33-76); BRCA2 were older than BRCA1 carriers (62 vs 51). Most pts presented at advanced stage (70% stages III-IV; 30% stage I-II). Seventeen were BRCA1 carriers and 6 were BRCA2 (5 of those PFM, a large insertion of an Alu element). Somatic correlation: 8 pts (5 BRCA1, 3PFM) were already analysed and 100% correlation was observed for all point mutations. One additional BRCA2 somatic mutation was detected (with a variant allele frequency of 53% whereas 2 others were &lt; 7%); interestingly exclusive somatic mutations were only observed in PFM carriers (known not to be NGS detectable). The remaining 15 pts are under analysis. Conclusions: it was expected that the PFM and other large rearrangements would not be detected with NGS. A specific somatic screening for the PFM may be possible but other rearrangements are found by MLPA in our population (10% of all BRCA mutations). Preliminary data adds to the evidence that NGS OC somatic screening will identify all germinal point mutations and an indeterminate number of additional pts with exclusive somatic mutations. An ideal correlation needs integration of differenttechniques that may increase complexity, time and cost.
Ferric Carboxymaltose to Treat Isovolemic Anemia—Reply
Authors: Young-Woo Kim, Hannah Yang
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Investigation of the clinicopathological features of vulva cancer: a retrospective survey of the JGOG Net Work study
Authors: S. Nishio, T. Shibata, S. Yamaguchi, H. Kanao, A. Kojima, M. Takekuma, A. Tozawa, H. Tokunaga, E. Miyagi, H. Kato, K. Kurihara, T. Yanase, K. Ushijima, M. Mikami, T. Sugiyama
Journal: Annals of Oncology (2017)
In utero negativization of Zika virus in a foetus with serious central nervous system abnormalities
Authors: C. Rodó, A. Suy, E. Sulleiro, A. Soriano-Arandes, A. Antón, I. García-Ruiz, S. Arévalo, É. Vázquez, A. Vázquez, F. de Ory, M.P. Sánchez-Seco, C. Rodrigo, T. Pumarola, E. Carreras
Journal: Clinical Microbiology and Infection (2017)
Occupational exposure to disinfectants and asthma control in US nurses
Authors: Orianne Dumas, Aleta S. Wiley, Catherine Quinot, Raphaëlle Varraso, Jan-Paul Zock, Paul K. Henneberger, Frank E. Speizer, Nicole Le Moual, Carlos A. Camargo
Journal: European Respiratory Journal (2017)

Disinfectant use has been associated with adverse respiratory effects among healthcare workers. However, the specific harmful agents have not been elucidated. We examined the association between occupational exposure to disinfectants and asthma control in the Nurses' Health Study II, a large cohort of female nurses.Nurses with asthma were invited in 2014 to complete two questionnaires on their current occupation and asthma (response rate 80%). Asthma control was defined by the Asthma Control Test (ACT). Exposure to major disinfectants was evaluated by a job-task-exposure matrix (JTEM).Analyses included 4102 nurses with asthma (mean age 58 years). Asthma control was poor (ACT score 16-19) in 12% of nurses and very poor (ACT score ≤15) in 6% of nurses. Use of disinfectants to clean medical instruments (19% exposed) was associated with poorly (OR 1.37; 95% CI 1.05-1.79) and very poorly (OR 1.88, 95% CI 1.38-2.56) controlled asthma (ptrend=0.004, after adjustment for potential confounders). Using JTEM estimates, exposure to formaldehyde, glutaraldehyde, hypochlorite bleach, hydrogen peroxide and enzymatic cleaners was associated with poor asthma control (all ptrend<0.05); exposure to quaternary ammonium compounds and alcohol was not.Use of several disinfectants was associated with poor asthma control. Our findings suggest targets for future efforts to prevent worsening of asthma control in healthcare workers.
Risk of second malignancies after definitive therapy for esophageal cancer: A competing risk analysis
Authors: S. Mitani, I. Oze, S. Kadowaki, T. Masuishi, Y. Narita, H. Taniguchi, T. Ura, M. Ando, M. Tajika, C. Makita, T. Kodaira, N. Uemura, T. Abe, K. Muro
Journal: Annals of Oncology (2017)
A phase II trial of pan-HER inhibitor Poziotinib, in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens: The results of NOV120101-203 trial
Authors: Y.H. Park, K-H. Lee, J. Sohn, K.S. Lee, K.H. Jung, J.H. Kim, K.H. Lee, J.S. Ahn, T-Y. Kim, G.M. Kim, I.H. Park, S-B. Kim, S.H. Kim, H.S. Han, Y-H. Im, J.H. Ahn, J-Y. Kim, J. Kang, S-A. Im
Journal: Annals of Oncology (2017)
EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC)
Authors: M. Martin Jimenez, T. Bachelot, C. Barrios, K. Blackwell, S. Chia, M. De Laurentiis, S. Hurvitz, W. Janni, B. Kaufman, S. Loi, P. Schmid, D. Slamon, K. Hazell, S. Mondal, M. Shilkrut, C. Germa, G. Hortobagyi
Journal: Annals of Oncology (2017)
PD-L1 expression in TNBC: A predictive biomarker of response to neoadjuvant chemotherapy?
Authors: A. Botticelli, B. Cerbelli, A. Pernazza, C.E. Onesti, P. Sciattella, L. Costarelli, M. Monti, D. Campagna, F. Mazzuca, L. Fortunato, P. Marchetti, G. D'Amati
Journal: Annals of Oncology (2017)
Aiming for zero tuberculosis transmission in low-burden countries
Authors: Ben J Marais, Timothy M Walker, Daniela M Cirillo, Mario Raviglione, Ibrahim Abubakar, Marieke J van der Werf, Catharina Boehme, Stefan Niemann, Kenneth G Castro, Alimuddin Zumla, Vitali Sintchenko, Derrick W Crook
Journal: The Lancet Respiratory Medicine (2017)
Rapid sensitisation and exacerbation of preexisting bystander-inflammation by intranasal exposure with ragweed pollen extract.
Authors: M. Kamml, F. Alessandrini, S. Oeder, S. Gilles, V. Marzaioli, U. Kanter, M. Hauser, J. Durner, J. Ring, F. Ferreira, D. Ernst, C. Traidl-Hoffmann, C Schmidt-Weber, H. Behrendt, Jan Gutermuth
Journal: Allergy (2012)
Reply to Parham Habibzadeh and Farrokh Habibzadeh's Letter to the Editor re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. Eur Urol 2017;72:942–9. The Most Appropriate IsoPSA Cutoff for Diagnosis of Prostate Cancer
Authors: Eric A. Klein
Journal: European Urology (2017)
ONCOS-102 and pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma
Authors: S. Ponce Aix, S. Viteri, J. Bosch-Borrera, L. Kuryk, T. Hakonen, S. Vetrhus, M. Jäderberg, L. Paz-Ares
Journal: Annals of Oncology (2017)
Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains
Authors: Frédéric Le Gal, Ségolène Brichler, Tudor Drugan, Chakib Alloui, Dominique Roulot, Jean‐Michel Pawlotsky, Paul Dény, Emmanuel Gordien
Journal: Hepatology (2017)

Hepatitis delta virus (HDV) is responsible for the most severe form of acute and chronic viral hepatitis. We previously proposed that the Deltavirus genus is composed of eight major clades. However, few sequences were available to confirm this classification. Moreover, little is known about the structural and functional consequences of HDV variability. One practical consequence is the failure of most quantification assays to properly detect or quantify plasmatic HDV RNA. Between 2001 and 2014, 2,152 HDV strains were prospectively collected and genotyped in our reference laboratory by means of nucleotide sequencing and extensive phylogenetic analyses of a 400‐nucleotide region of the genome ( R0 ) from nucleotides 889 to 1289 encompassing the 3′ end of the delta protein–coding gene. In addition, the full‐length genome sequence was generated for 116 strains selected from the different clusters, allowing for in‐depth characterization of the HDV genotypes and subgenotypes. This study confirms that the HDV genus is composed of eight genotypes (HDV‐1 to HDV‐8) defined by an intergenotype similarity &gt;85% or &gt;80%, according to the partial or full‐length genome sequence, respectively. Furthermore, genotypes can be segregated into two to four subgenotypes, characterized by an intersubgenotype similarity &gt;90% (&gt;84% for HDV‐1) over the whole genome sequence. Systematic analysis of genome and protein sequences revealed highly conserved functional nucleotide and amino acid motifs and positions across all (sub)genotypes, indicating strong conservatory constraints on the structure and function of the genome and the protein. Conclusion: This study provides insight into the genetic diversity of HDV and a clear view of its geographical localization and allows speculation as to the worldwide spread of the virus, very likely from an initial African origin. (H epatology 2017;66:1826–1841)
Poor Outcomes in Poor Patients?
Authors: Johann Bauersachs
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Scapular dyskinesis and shoulder pain: the devil is in the detail
Authors: Chris Littlewood, Ann M J Cools
Journal: British Journal of Sports Medicine (2017)

The systematic review by Hickey et al 1 evaluated whether the presence of scapular dyskinesis in asymptomatic athletes increased risk of developing future shoulder pain. This review was conducted on the backdrop of conflicting evidence and concluded that athletes with scapular dyskinesis have 43% greater risk of developing shoulder pain than those without scapular dyskinesis. This headline is an interesting finding that appears to add some clarity to the many unknowns in relation to assessment and management of shoulder pain. However, as is always the case with research, the devil is in the detail, which warrants further consideration.

The review reports that 65% (104/160) of those with scapular dyskinesis did not go on to develop shoulder pain, whereas 25% (65/259) of those without scapular dyskinesis did. As the authors reflect, an increased risk informs us only that there is an increased chance of developing shoulder pain, but is not a guarantee that it will, that is, the presence of scapular dyskinesis does not guarantee that an athlete will develop shoulder pain nor does its …
Infectious disease screening in asylum seekers: range, coverage and economic evaluation in Germany, 2015
Authors: Kayvan Bozorgmehr, Katharina Wahedi, Stefan Noest, Joachim Szecsenyi, Oliver Razum
Journal: Eurosurveillance (2017)

Screening asylum seekers for infectious diseases is widely performed, but economic evaluations of such are scarce. We performed a policy analysis and economic evaluation of such screening in Germany, and analysed the effect of screening policies on cost differences between federal states. Of the 16 states, screening was compulsory for tuberculosis (TB) in asylum seekers ≥ 16 years of age in all states as well as in children < 16 years of age and pregnant women in six states, hepatitis B and enteropathogens in three, syphilis in two and human immunodeficiency virus (HIV) in one state. Of 441,899 asylum seekers, 88.0% were screened for TB, 22.9% for enteropathogens, 16.9% for hepatitis B, 13.1% for syphilis and 11.3% for HIV. The total costs for compulsory screening in 2015 were 10.3 million euros (EUR). Costs per case were highest for infections with Shigella spp. (80,200 EUR), Salmonella spp. (8,000 EUR), TB in those ≥ 16 years of age (5,300 EUR) and syphilis (1,150 EUR). States with extended screening had per capita costs 2.84 times those of states that exclusively screened for TB in asylum seekers ≥ 16 years of age (p < 0.0001, 95% confidence interval (CI): 1.96-4.10). Screening practices in Germany entailed high costs; evidence-based approaches to infectious disease screening are needed.
Atlas of Extraosseous Findings Detected by 18F-NaF PET/CT Bone Scan
Authors: Gregory J. Woodhead, Ryan J. Avery, Phillip H. Kuo
Journal: Clinical Nuclear Medicine (2017)

F-NaF PET/CT is an evolving technique that provides high sensitivity for detection of osseous metastases. In addition to detecting pathological osseous lesions, F uptake is occasionally detected in extraosseous lesions. However, reporting of extraosseous uptake in the literature is limited, and the increasing use of F-NaF PET/CT dictates that interpreting physicians learn to recognize extraosseous findings. An atlas of extraosseous findings detected by F-NaF PET/CT is presented, which includes cases under 2 broad categories: nonneoplastic and neoplastic.
Safety vs Efficacy of Lowering Blood Pressure—Reply
Authors: Joshua D. Bundy, Paul K. Whelton, Jiang He
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Comments on “Vitamin Pharmacogenomics: New Insight into Individual Differences in Diseases and Drug Responses”
Authors: Tom Greenfield
Journal: Genomics Proteomics & Bioinformatics (2017)

the glycosylation of B 12 -binding proteins and their receptors including transcobalamin I, GIF, cubilin, and CD320.The authors state however that the mechanism through which the FUTs act upon these B 12 -binding proteins and their receptors is unclear and needs to be investigated further.
Is CT-based selective nodal irradiation safe for clinical stage N0-1 LD-SCLC patients?
Authors: Man Hu, Bingjie Fan, Li Kong, Jinming Yu
Journal: Journal of Clinical Oncology (2013)

e18551 Background: Radiotherapy plays an important role in the management of limited-disease small-cell lung cancer (LD-SCLC). However, volume of irradiation remains unanswered as well as optimal total dose, timing and sequencing of radiation. In this study, we compared the clinical lymph node staging with pathological staging, with the aim of investigating the safety of CT-based selective nodal irradiation for clinical stage N0-1 LD-SCLC patients. Methods: From July 2004 to March 2012, 20 potentially operable patients with clinical stage N0-1 LD-SCLC underwent contrast-enhanced CT scans and other routine initial staging procedures followed by radical resection of primary tumor and systemic intra-thoracic lymph node dissection. The results of reviewing clinical staging for the mediastinal lymph node metastases were compared with pathologic findings. Results: Preoperative nodal staging was compared with postoperative pathological staging, 35% (7 of 20) of patients were under staged by clinical staging. Of all the 7 patients with mediastinal lymph node metastases, 4 patients (57.1%) had subcrinal nodes (station 7) metastases, 1 had right upper paratracheal nodes (station 2R) metastases, 1 had left lower paratracheal nodes (station 4L) metastases, 1 had aortopulmonary nodes (station 5) metastases. Conclusions: CT-based selective nodal irradiation for LD-SCLC may result in geographical miss in clinical stage N0-1 patients. Mediastinal lymph node regions especially the subcrinal nodes should be contained in the clinical target volume for radiotherapy.
Reactivación de hepatitis B en un unidad de diálisis de Irlanda, 2005
Authors: L Thornton, F Fitzpatrick, D de la Harpe, S Brennan, N Murphy, J Connell, H Humphreys, E Smyth, J J Walshe, M Crean, D O’ Flanagan
Journal: Eurosurveillance (2007)

En abril de 2005, se produjo un caso de reactivacion de la infeccion por el virus de la hepatitis B (VHB) en un paciente sometido a hemodialisis en un hospital en Irlanda. Este incidente podria haber afectado a pacientes atendidos en hospitales de todo el pais, por lo que se designo un equipo nacional de incidencias par coordinar la respuesta al incidente.
FRI0052 To evaluate antibodies antinuclear (ana) in rheumatoid arthritis with infliximab treatmentoid
Authors: F Gamero- Ruiz, G Bonilla, G Diaz, JM Gonzalez-Tarrio, R Alvarez-Doforno, A Balsa, E Martin-Mola
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To examine the evolution of the ANA titre in patients with rheumatoid arthritis treated with infliximab (anti TNF- alpha). <h3>Methods</h3> 14 patients with active rheumatoid arthritis and unresponsive to at least 3 DMARDs were treated with methotrexate and infliximab. Before infliximab infusion, weeks 0, 2,6,14 and 22, a physical examination, DAS 28 and blood test, which included RF, ANA, immunoglobulin quantification C3 and C4 were done. <h3>Results</h3> At the baseline visit 5/14 (35,71%) patients had positive ANA test,2 (1/40),1 (1/80),1 (1/160), 1 (1/640). After the fifth infusion 8/14 (57,14%) had a positive ANA test. Three patients who initially were ANA negative showed a titre of 1/160,1/320 and 1/640. Three out of 5 patients which previously had a positive test, showed an increase in the ANA titre,1/40 to 1/80,1/40 to 1/320 and 1/640 to 1/1280. After the fourth infusion of infliximab, all patients with ANA positive had a Crithidia test performed. In all cases anti DNA were negative. <h3>Conclusion</h3> In our experience, treatment with infliximab has shown an increase of the ANA titre in 21,42% of the patients. On the other hand, 21,4% of the patients with a previous negative test for ANA had a positive test after the fourth infusion. All cases were negative for anti-DNA antibodies.